TISSUE BIOLOGY · STATE + ENERGY
Cellular-energy, state-transition, and cancer studies answer different questions. Each finding stays beside the model, dosage direction, direct result, and limit that define what it can support.
CELLULAR ENERGY · EVIDENCE LIMITS
Cellular-energy questions belong inside tissue and cell-state biology. A cellular measurement, a disease diagnosis, a person-level phenotype, and a patient-allele mechanism are separate claims.
Fatigue, feeding, illness recovery, exercise tolerance, temperature, or state-sensitive function can motivate ordinary clinical assessment. These observations are nonspecific.
Blood, urine, nutrition, endocrine, or organ-function studies answer the clinical question and time window for which they were obtained.
Respiration, membrane potential, enzyme activity, metabolites, or imaging remain attached to the named specimen, method, reference, and state.
Repeat sampling, an independent laboratory, another relevant tissue, or a validated model asks whether the result is reproducible.
An isogenic model asks whether a specific ASH1L allele produces the readout and whether correction or defined rescue reverses it.
Requires convergent evidence across allele, cell identity, state, time, mechanism, and rescue. This level is not currently established.
MODEL-SYSTEM EVIDENCE
A 2026 study included ASH1L knockout across defined human neural cell states. ASH1L contributed to a pooled mitochondrial membrane-potential signal, while an arrayed follow-up did not show a significant ASH1L effect on Seahorse respiratory parameters.
What this does not establish: this is engineered gene-loss evidence—not a patient-allele assay, clinical biomarker, or mitochondrial diagnosis.
Open the primary study ↗HOW TO TEST IT
Compare a patient-derived allele, corrected isogenic control, calibrated dosage series, and defined rescue in relevant cell states. Measure energy readouts together with ASH1L dosage, chromatin, cell identity, viability, and recovery.
How to read the result: support, refine, or weaken the model according to replication, state specificity, alternatives, and rescue—not one abnormal value.
Open the full experimental design PDF →What the evidence supports: cellular-energy measurement questions. It does not support a supplement recommendation or one shared mitochondrial phenotype.
DISTINCT STATE QUESTIONS
The evidence below concerns proliferation, differentiation, quiescence, inflammatory restraint, repair, resorption, or memory stabilization in different systems. “Failure to terminate” is not one mechanism; it must be decomposed into the specific entry, exit, maintenance, or recovery process that an experiment can measure.
Scroll horizontally to review every column.
| System | Direct result | What it does not establish | Source |
|---|---|---|---|
| Neural progenitor | Arrayed ASH1L knockout increased the proportion of Ki-67-positive progenitors. | This supports altered proliferative state; it does not directly prove a universal failure of neuronal differentiation. | Primary study ↗ |
| Hematopoietic stem cell | Ash1l-deficient cells failed to establish the normal quiescent adult stem-cell pool. | Fetal Sox17 and Lin28b programs were still extinguished, so the experiment does not show persistence of a global fetal state. | Primary study ↗ |
| Epidermis | Ash1l disruption altered the proliferation–differentiation balance, stratification, and wound re-epithelialization. | A hypomorphic mouse-skin result is not proof of a shared human wound-healing mechanism. | Primary study ↗ |
| Immune lineages | Separate models show roles in macrophage inflammatory restraint and induced regulatory-T-cell polarization. | They do not establish one human immune phenotype, occult inflammation, or immune-directed treatment. | Macrophage model ↗Regulatory T-cell model ↗ |
| Muscle and bone | Experimental studies connect Ash1l to myoblast fusion and osteoclast differentiation or resorption. | These models do not establish that human weakness, hypermobility, fractures, or low bone density share one cause. | Myoblast model ↗Osteoclast model ↗ |
| Memory circuit | ASH1L was required for later stabilization of selected memories in one thalamocortical mouse task. | This is maintenance in a defined circuit—not evidence of global human regression or neurodegeneration. | Primary study ↗ |
HOW TO TEST THE HYPOTHESIS
Measure the baseline, defined perturbation, peak, shutoff, recovery, and repeat challenge in the relevant cell type. Separate response magnitude from response duration, persistent trigger, medication effect, and unrelated disease.
A DIFFERENT DOSAGE CONTEXT
ASH1L activity has been studied in KMT2A-rearranged leukemia and anaplastic thyroid-cancer models, often in settings of excess activity, overexpression, or tumor-specific dependency. Those experiments are valuable for catalytic and chromatin biology.
They do not establish that people with germline ASH1L haploinsufficiency have increased cancer risk, and an ASH1L inhibitor developed for leukemia is not a treatment rationale for ASH1L loss of function.